Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 200

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers

Open access
Goldstein, Leonard D., Lee, James, Gnad, Florian, Klijn, Christiaan, Schaub, Annalisa, Reeder, Jens, Daemen, Anneleen, Bakalarski, Corey E., Holcomb, Thomas, Shames, David S., Hartmaier, Ryan J., Chmielecki, Juliann, Seshagiri, Somasekar, Gentleman, Robert, Stokoe, David·2016·Cell Reports

Abstract

The Nrf2 pathway is frequently activated in human cancers through mutations in Nrf2 or its negative regulator KEAP1. Using a cell-line-derived gene signature for Nrf2 pathway activation, we found that some tumors show high Nrf2 activity in the absence of known mutations in the pathway. An analysis of splice variants in oncogenes revealed that such tumors express abnormal transcript variants from the NFE2L2 gene (encoding Nrf2) that lack exon 2, or exons 2 and 3, and encode Nrf2 protein isoforms missing the KEAP1 interaction domain. The Nrf2 alterations result in the loss of interaction with KEAP1, Nrf2 stabilization, induction of a Nrf2 transcriptional response, and Nrf2 pathway dependence. In all analyzed cases, transcript variants were the result of heterozygous genomic microdeletions. Thus, we identify an alternative mechanism for Nrf2 pathway activation in human tumors and elucidate its functional consequences.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.celrep.2016.08.010

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 29

  1. An, 2015, Truncated ERG oncoproteins from TMPRSS2-ERG fusions are resistant to SPOP-mediated proteasome degradation, Mol. Cell, 59, 904, 10.1016/j.molcel.2015.07.025 · DOI
  2. Anders, 2010, Differential expression analysis for sequence count data, Genome Biol., 11, R106, 10.1186/gb-2010-11-10-r106 · DOI · Paper page
  3. Baba, 2013, Seven in absentia homolog 2 (Siah2) protein is a regulator of NF-E2-related factor 2 (Nrf2), J. Biol. Chem., 288, 18393, 10.1074/jbc.M112.438762 · DOI
  4. Cho, 2011, Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies, Cancer Res., 71, 7587, 10.1158/0008-5472.CAN-11-0821 · DOI
  5. Chorley, 2012, Identification of novel NRF2-regulated genes by ChIP-seq: influence on retinoid X receptor alpha, Nucleic Acids Res., 40, 7416, 10.1093/nar/gks409 · DOI · Paper page
  6. Chowdhry, 2013, Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity, Oncogene, 32, 3765, 10.1038/onc.2012.388 · DOI · Paper page
  7. DeNicola, 2015, NRF2 regulates serine biosynthesis in non-small cell lung cancer, Nat. Genet., 47, 1475, 10.1038/ng.3421 · DOI · Paper page
  8. Fukutomi, 2014, Kinetic, thermodynamic, and structural characterizations of the association between Nrf2-DLGex degron and Keap1, Mol. Cell. Biol., 34, 832, 10.1128/MCB.01191-13 · DOI · Paper page
  9. Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci. Signal., 6, pl1, 10.1126/scisignal.2004088 · DOI · Paper page
  10. George, 2015, Comprehensive genomic profiles of small cell lung cancer, Nature, 524, 47, 10.1038/nature14664 · DOI · Paper page
  11. Goldstein, 2016, Prediction and Quantification of Splice Events from RNA-Seq Data, PLoS ONE, 11, e0156132, 10.1371/journal.pone.0156132 · DOI · Paper page
  12. Hart, 1999, The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell, Curr. Biol., 9, 207, 10.1016/S0960-9822(99)80091-8 · DOI · Paper page
  13. Hirotsu, 2012, Nrf2-MafG heterodimers contribute globally to antioxidant and metabolic networks, Nucleic Acids Res., 40, 10228, 10.1093/nar/gks827 · DOI · Paper page
  14. Iwao, 1998, Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations, Cancer Res., 58, 1021
  15. Kataoka, 2015, Integrated molecular analysis of adult T cell leukemia/lymphoma, Nat. Genet., 47, 1304, 10.1038/ng.3415 · DOI · Paper page
  16. Katoh, 2001, Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription, Genes Cells, 6, 857, 10.1046/j.1365-2443.2001.00469.x · DOI · Paper page
  17. Klijn, 2015, A comprehensive transcriptional portrait of human cancer cell lines, Nat. Biotechnol., 33, 306, 10.1038/nbt.3080 · DOI · Paper page
  18. Kong-Beltran, 2006, Somatic mutations lead to an oncogenic deletion of met in lung cancer, Cancer Res., 66, 283, 10.1158/0008-5472.CAN-05-2749 · DOI · Paper page
  19. Leinonen, 2014, Role of the Keap1-Nrf2 pathway in cancer, Adv. Cancer Res., 122, 281, 10.1016/B978-0-12-420117-0.00008-6 · DOI · Paper page
  20. MacLeod, 2009, Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds, Carcinogenesis, 30, 1571, 10.1093/carcin/bgp176 · DOI · Paper page
  21. Malhotra, 2010, Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-seq profiling and network analysis, Nucleic Acids Res., 38, 5718, 10.1093/nar/gkq212 · DOI · Paper page
  22. McMahon, 2006, Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a “tethering” mechanism: a two-site interaction model for the Nrf2-Keap1 complex, J. Biol. Chem., 281, 24756, 10.1074/jbc.M601119200 · DOI · Paper page
  23. Pruitt, 2005, NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins, Nucleic Acids Res., 33, D501, 10.1093/nar/gki025 · DOI · Paper page
  24. Riccardi, 2006, Analysis of apoptosis by propidium iodide staining and flow cytometry, Nat. Protoc., 1, 1458, 10.1038/nprot.2006.238 · DOI · Paper page
  25. Rosenbloom, 2015, The UCSC Genome Browser database: 2015 update, Nucleic Acids Res., 43, D670, 10.1093/nar/gku1177 · DOI · Paper page
  26. Sekine, 2015, The mediator subunit MED16 transduces NRF2-activating signals into antioxidant gene expression, Mol. Cell. Biol., 36, 407, 10.1128/MCB.00785-15 · DOI
  27. Shibata, 2008, Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy, Proc. Natl. Acad. Sci. USA, 105, 13568, 10.1073/pnas.0806268105 · DOI · Paper page
  28. Vitari, 2011, COP1 is a tumour suppressor that causes degradation of ETS transcription factors, Nature, 474, 403, 10.1038/nature10005 · DOI · Paper page
  29. Zhang, 2006, BRG1 interacts with Nrf2 to selectively mediate HO-1 induction in response to oxidative stress, Mol. Cell. Biol., 26, 7942, 10.1128/MCB.00700-06 · DOI · Paper page

Cited by

See all 200

Metadata

Authors
Goldstein, L. D., Lee, J., Gnad, F., Klijn, C., Schaub, A., Reeder, J., Daemen, A., Bakalarski, C. E., Holcomb, T., Shames, D. S., Hartmaier, R. J., Chmielecki, J., Seshagiri, S., Gentleman, R., & Stokoe, D.
Venue
Cell Reports
Publisher
Elsevier BV
Published
2016-09
Volume
16
Issue
10
Pages
2605-2617
ISSN
2211-1247 (ISSN-L)
OpenAlex
W2515118862
Cited by
200
References
12
FWCI
8.13
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers. https://app.cochat.ai/papers/10.1016/j.celrep.2016.08.010
The paper
Goldstein, L. D., Lee, J., Gnad, F., Klijn, C., Schaub, A., Reeder, J., Daemen, A., Bakalarski, C. E., Holcomb, T., Shames, D. S., Hartmaier, R. J., Chmielecki, J., Seshagiri, S., Gentleman, R., & Stokoe, D. (2016). Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers. Cell Reports. https://doi.org/10.1016/j.celrep.2016.08.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.